In joining ALZHEON, Peter brings unparalleled depth of expertise in shaping the Alzheimer’s Commercial landscape over his 20+ year career in both large Pharma (Pfizer Inc.), and rising Biotech (Elan, Merrimack, Tesaro). At Pfizer, with their partners Eisai Inc., he launched ARICEPT©- the first meaningful treatment for AD, to achieve peak sales exceeding $ 3B. Subsequently, at Elan as VP Strategic Brand Management, he led commercial development of the first anti-amyloid antibody – bapineuzumab.
As Group Leader, Pfizer US Oncology Marketing, Peter oversaw the launch of SUTENT© – a breakthrough drug for Renal Cell Carcinoma and GIST. At Merrimack, as SVP, Head of Late-stage Development he led Phase 3 and successful FDA approval of ONIVYDE© – the first new therapy for metastatic Pancreatic cancer in 20 years, and supported a $1B Sale transaction of the asset.
Prior to ALZHEON, Peter served as SVP, Strategic Development Program Management & Portfolio Assessment at Tesaro, as well as managing R&D Leadership, Governance, and Decision processes.
A graduate of McGill University (Montreal) with a Bsc in Microbiology and Immunology, and MBA in Marketing and Corporate Policy, Peter is originally from Montreal Canada, and now resides with his wife and children in Scituate Mass., south of Boston.
Peter strongly believes that winning Commercial development strategy is grounded in deep competitive and customer insights, coupled with agile, fit-for-purpose execution. Through integrity, independence of thought, and diversity of experience, he brings a powerful combination of qualities so important to rising biotechs such as ALZHEON.